HC Wainwright & Co. Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Neutral 65.5%

Neg 0% Neu 65.5% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $45.